RT Journal Article
SR Electronic
T1 Neutralizing Antibody to Omicron BA.1, BA.2 and BA.5 in COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.21.22278552
DO 10.1101/2022.08.21.22278552
A1 Linderman, Susanne L.
A1 Lai, Lilin
A1 Bocangel Gamarra, Estefany L.
A1 Mohr, Nicholas M.
A1 Gibbs, Kevin W.
A1 Steingrub, Jay S.
A1 Exline, Matthew C.
A1 Shapiro, Nathan I.
A1 Frosch, Anne E.
A1 Qadir, Nida
A1 Edupuganti, Srilatha
A1 Surie, Diya
A1 Tenforde, Mark W.
A1 Davis-Gardner, Meredith E.
A1 Chappell, James D.
A1 Lau, Max S Y
A1 McElrath, M. Juliana
A1 Lauring, Adam S.
A1 Suthar, Mehul S.
A1 Patel, Manish M.
A1 Self, Wesley H.
A1 Ahmed, Rafi
YR 2022
UL http://medrxiv.org/content/early/2022/08/22/2022.08.21.22278552.abstract
AB Neutralizing antibody plays a key role in protective immunity against COVID-19. As increasingly distinct variants circulate, debate continues regarding the value of adding novel variants to SARS-CoV-2 vaccines. In this study, we have analyzed live virus neutralization titers against WA1, Delta, BA.1, BA.2, and BA.5 in 187 hospitalized patients infected with Delta or Omicron strains. This information will be useful in selection of the SARS-CoV-2 strains to include in an updated vaccine. Our results show that unvaccinated Delta infected patients made a highly biased neutralizing antibody response towards the infecting Delta strain with slightly lower responses against the WA1 strain, but with strikingly lower titers against BA.1, BA.2, and BA.5. Delta infected patients that had been previously vaccinated with the WA1 containing COVID vaccine made equivalent responses to WA1 and Delta strains, but still had very low neutralizing antibody responses to Omicron strains. In striking contrast, both unvaccinated and vaccinated Omicron patients exhibited a more balanced ratio of Omicron virus neutralization compared to neutralization of ancestral strains. Interestingly, Omicron patients infected with BA.1 or BA.2 had detectable neutralizing antibody titers to BA.5, but these titers were lower than neutralization titers to BA.1 and BA.2. Taken together, these results suggest that inclusion of the Omicron BA.5 strain in a SARS-CoV-2 vaccine would be beneficial in protection against the widely circulating BA.5 variant.Disclaimer The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has been funded in part by grants (NIH P51OD011132, 3U19AI057266-17S1, 1U54CA260563, HHSN272201400004C, NIH/NIAID CEIRR under contract 75N93021C00017 to Emory University) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This work was also supported in part by the Emory Executive Vice President for Health Affairs Synergy Fund award, COVID-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine, the Pediatric Research Alliance Center for Childhood Infections and Vaccines and Childrens Healthcare of Atlanta, and Woodruff Health Sciences Center 2020 COVID-19 CURE Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This prospective, multicenter observational assessment was conducted by the Influenza and Other Viruses in the Acutely Ill (IVY) Network in collaboration with the US Centers for Disease Control and Prevention (CDC). The IVY Network is a 21-hospital collaborative in the US studying COVID-19. Eight hospitals participated in the serology component included in the current analysis. These activities were reviewed by CDC, were conducted consistent with applicable federal law and CDC policy (45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. 241(d); 5 U.S.C. 552a; 44 U.S.C. 3501 et seq), and were determined to be public health surveillance with waiver of informed consent by institutional review boards at CDC and each enrolling site.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors